unknown
Stage
1
Investors
About
Affimed is a clinical-stage biotechnology company developing innate cell-engaging (ICE) antibody platforms and cell therapies to treat cancer. Its programs focus on engaging NK and T cells to target hematological malignancies and solid tumors.
Explore Affimed's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.